More than two years after France, Great Britain decides to warn patients of the risks of venous thrombosis linked to the use of 3rd and 4th generation contraception.
Watch out for 3 pillse and 4e generation across the Channel. The British Medicines and Healthcare Products Regulatory Agency (MHRA) has sent a letter to general practitioners. She asks them to warn patients using this method of contraception of the risk of blood clot formation.
About one million women use contraception of 3e or 4e generation in Britain. Finally, they will be warned of the risk of venous thrombosis associated with these drugs. Without going so far as to ask to limit prescriptions, the MHRA asks doctors to discuss the subject with their patients. A very late warning when we know that since 2011, the National Medicines Safety Agency (ANSM) has been communicating on the subject.
But Europe refuses to downgrade the risk-benefit ratio of 3 pillse and 4e generation. Seized three times by France, the European Medicines Agency (EMA) considers that the risk of venous thromboembolism is low. However, it calls for a revision of the instructions, so that patients at risk are warned of this risk. The MHRA simply applies these recommendations.
France went further, which earned it many criticisms. The ANSM encouraged general practitioners and specialists to limit the prescription of contraceptives to a minimum of 3e and 4e generation. In his last point of September 2013, she estimated the drop in prescriptions for these pills to be 50%. This decision resulted from a report for these drugs which identified, between 2000 and 2011, 20 deaths from venous thromboembolism each year because of the taking of this contraception.
.
